Lilly Builds On Innovent Biologics China Bet

Eli Lilly and Company has expanded its cancer drug collaboration with Chinese biotech Innovent Biologics Inc with plans to develop and market up to three anti-PD-1 based bi-specific antibodies over the next decade, both inside China's expanding healthcare market and abroad.